X4 Pharmaceuticals (XFOR) to Release Earnings on Thursday

X4 Pharmaceuticals (NASDAQ:XFOR) is projected to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect X4 Pharmaceuticals to post earnings of ($0.20) per share and revenue of $3.20 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 9:30 AM ET.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.14. The firm had revenue of $2.57 million for the quarter, compared to the consensus estimate of $1.68 million. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative return on equity of 115.27%. On average, analysts expect X4 Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

X4 Pharmaceuticals Stock Up 0.5%

Shares of NASDAQ XFOR opened at $4.21 on Tuesday. The company has a market capitalization of $382.77 million, a P/E ratio of -0.97 and a beta of 0.31. X4 Pharmaceuticals has a 52-week low of $1.35 and a 52-week high of $4.83. The company has a debt-to-equity ratio of 0.41, a quick ratio of 9.98 and a current ratio of 10.16. The company’s 50 day moving average price is $3.97 and its 200-day moving average price is $3.79.

Analysts Set New Price Targets

Several analysts have recently weighed in on XFOR shares. Weiss Ratings upgraded shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, April 24th. Guggenheim initiated coverage on shares of X4 Pharmaceuticals in a research report on Monday, March 9th. They set a “buy” rating and a $12.00 target price on the stock. Finally, Wall Street Zen upgraded shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $8.50.

Institutional Trading of X4 Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC bought a new stake in X4 Pharmaceuticals during the 4th quarter valued at $50,000. Two Sigma Investments LP bought a new stake in X4 Pharmaceuticals during the 3rd quarter valued at $47,000. Stifel Financial Corp bought a new stake in X4 Pharmaceuticals during the 4th quarter valued at $82,000. Virtu Financial LLC bought a new stake in X4 Pharmaceuticals during the 4th quarter valued at $90,000. Finally, Man Group plc bought a new stake in X4 Pharmaceuticals during the 4th quarter valued at $97,000. Institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.